Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;202(3):325-330.
doi: 10.1007/s00408-024-00692-4. Epub 2024 Apr 18.

Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields

Lara M Khoury  1 , Kristin N Sheehan  2 , William I Mariencheck  2 , Katherine A Gershner  2 , Matthew Maslonka  3 , Angela G Niehaus  4 , Scott Isom  5 , Christina R Bellinger  2
Affiliations

Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields

Lara M Khoury et al. Lung. 2024 Jun.

Abstract

Purpose: Immunotherapy is a leading approach for treating advanced non-small cell lung cancer (NSCLC) by targeting the PD-1/PD-L1 checkpoint signaling pathway, particularly in tumors expressing high levels of PD-L1 (Jug et al. in J Am Soc Cytopathol 9:485-493, 2020; Perrotta et al. in Chest 158: 1230-1239, 2020). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive method to obtain tissue for molecular studies, including PD-L1 analysis, in unresectable tumors (Genova et al. in Front Immunol 12: 799455, 2021; Wang et al. in Ann Oncol 29: 1417-1422, 2018). This study aimed to assess the adequacy of PD-L1 assessment in EBUS-TBNA cytology specimens.

Methods: Data was collected retrospectively from patients who underwent EBUS-TBNA between 2017 and 2021 for suspected lung cancer biopsy. Samples positive for NSCLC were examined for PD-L1 expression. EBUS was performed by experienced practitioners, following institutional guidelines of a minimum of five aspirations from positively identified lesions. Sample adequacy for molecular testing was determined by the pathology department.

Results: The analysis involved 387 NSCLC cases (149 squamous cell, 191 adenocarcinoma, 47 unspecified). Of the 263 EBUS-TBNA specimens tested for PD-L1, 237 (90.1%) were deemed adequate. While 84% adhered to the protocol, adherence did not yield better results. Significantly higher PD-L1 adequacy was observed in squamous cell carcinomas (93.2%) compared to adenocarcinoma (87.6%). The number of aspirations and sedation type did not correlate with PD-L1 adequacy in either cancer type, but lesion size and location had a significant impact in adenocarcinomas. Adenocarcinoma exhibited higher PD-L1 expression (68%) compared to squamous cell carcinoma (48%).

Conclusion: EBUS-TBNA offers high yields for assessing immunotherapy markers like PD-L1, with satisfactory adequacy regardless of NSCLC subtype, lesion size, or location.

Keywords: Bronchoscopy; EBUS-TBNA; Lung cancer; Molecular markers; PD-L1 yields.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts interest to declare.

References

    1. Jug R, Giovacchini CX, Liu B, et al. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer. J Am Soc Cytopathol. 2020;9:485–493. doi: 10.1016/j.jasc.2020.04.003. - DOI - PMC - PubMed
    1. Perrotta F, Nankivell M, Adizie JB, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest. 2020;158:1230–1239. doi: 10.1016/j.chest.2020.04.059. - DOI - PubMed
    1. Genova C, Dellepiane C, Carrega P, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade. Front Immunol. 2021;12:799455. doi: 10.3389/fimmu.2021.799455. - DOI - PMC - PubMed
    1. Wang H, Agulnik J, Kasymjanova G, et al. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Ann Oncol. 2018;29:1417–1422. doi: 10.1093/annonc/mdy126. - DOI - PubMed
    1. Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) BMC Cancer. 2020;20:1185. doi: 10.1186/s12885-020-07690-8. - DOI - PMC - PubMed

Publication types